

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Mia LEVITE

Serial No.:

10/809,425

Filed:

March 26, 2004

For:

Methods Of And Pharmaceutical Compositions For Modulating

T-Lymphocyte Adhesion, Migration, Gene Expression And Function By Glutamate And Analogs Thereof

Examiner: JALLA, SANJOO

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Group Art Unit: 1644

Attorney

Docket: 27644

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Martin Moynihan

Registration No. 40,338

Dated: December 5, 2005

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995,

no posons are required to spond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)					Complete if Known				
					Application	on Number	10/809	,425	
					Filing Date March 26		26, 2004		
					First Nam	ed Inventor	Mia LEVITE		
					Art Unit 1644				
						Examiner	Name	JALLA	, SANJOO
Sheet		1	of	2		Attorney	Docket Number	27644	
			U.S.	PAT	ENT I	OCUMI	ENTS		
Examiner Initials*	Cite No. ¹			Publication Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Document			Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-4,946,778	07-7-199	90		-	Ladner et al.		
							-		
						-			
			ļ						
									-
							···-		
		<u>L</u>	L						
		• •	FOREI	GN I	PATEN	T DOCU	JMENTS		
Examiner Initials*	iner Cite			Publication Date		Name of Patentee or		Pages, Columns, Lines, Where Relevant Passages	

		FOREIGN	PATENT DOC	UMENTS			
Examiner Initials*	Cite No. 1	Foreign Patent Documents Country Code ³ Number ⁴ Kind Code ⁵ (if known)			of Patentee or of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
	2	PCT WO 99/50393	07-7-1999	Wank			П
	1						Ш
	-		<u> </u>				Ш
-	1						Н
Evamina	<u> </u>		<u>.</u>	<u> </u>	D-4-		Ш
Examiner Signature					Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

		bstitute for form 1449A/PTO	Complete if Known							
			Application Number 10/809							
	INF	ORMATION DISCLOSURE	Filing Date	March 26, 2004						
	STA	TEMENT BY APPLICANT	First Named Inventor	Mia LEVITE						
	5171	TEMENT BY ATTEICANT	Group Art Unit	1644						
		(use as many sheets as necessary)		Examiner Name	JALLA	, SANJOO				
Sheet	2	Of	2	Attorney Docket Number	27644					
		OTHER PRIOR ART – NON F								
Examiner	Cite			the article (when appropriate), title of the						
Initials	No.1	item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.								
	3	Sperner-Unterweger et al. "T-Cell Subsets in Schizophrenia: A Comparison Between								
		Drug-Naïve First Episode Patients and	phrenic Patients",							
	Schizophrenia Research, 38: 61-70, 1999.									
	4	Schwartz et al. "Protective Autoimmunity: Regulation and Prospects for Vaccination								
		After Brain and Spinal Cord Injuries", Trends in Molecular Medicine, 7(6): 252-258, 2001.								
	5	Schori et al. "T-Cell-Based Immunity Counteracts the Potential Toxicity of								
		Glutamate in the Central Nervous System", Journal of Neuroimmunology, 119: 199-								
		204, 2001.	,	83,						
	6	Kuo et al. "The Involvement of Glutar	nate in Recall of	the Conditioned NK Cel	1	٠.				
		Response", Journal of Neuroimmunology, 118: 245-255, 2001.								
	7	Riewald et al. "Expression of Bomapin, A Novel Human Serpin, in								
	'	Normal/Malignant Hematopoiesis and in the Monocytic Cell Lines THP-1 and AML-								
		193", Blood, 91(4): 1256-1262, 1998.								
····	8	Levite "Nervous Immunity: Neurotrar		ellular K+ and T-Cell						
		Function", Trends in Immunology, 22(1): 2-5, 2001.								
	9	Levite "Neuropeptides, by Direct Interaction Eith T Cells, Induce Cytokine Secretion								
		and Break the Commitment to A Distinct T Helper Phenotype", Proc. Natl. Acad.								
		Sci. USA, 95: 12544-12549, 1998.								
	10	Nakanishi et al. "Glutamate Receptors	Rrain Function	and Signal Transduction	.11					
	1.0	Brain Research Reviews, 26: 230-235		una orginar transduction	,					
	11	Yoles et al. "Protective Autoimmunity		cal Response to CNS Tra	uma".					
		The Journal of Neuroscience, 21(11):			,					
	12	Lombardi et al. "Characterization of I			,					
	1-	Lymphocytes", British Journal of Pha			•					
	<u> </u>	= 5 mphocytos ; 2 mon commi or i ma	macologj, 155.	330 3 1 1, 2001.						
		 	77 W W W W							
	_									
										
				,						
		1			i					

Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional).

2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.